Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sickle cell disease

P A Lane1

  • 1Department of Pediatrics, University of Colorado School of Medicine, Denver, USA.

Pediatric Clinics of North America
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Despite the lack of a cure for sickle cell disease (SCD), advances in understanding its pathophysiology have improved prophylactic and supportive therapies, significantly reducing morbidity and extending lifespan for patients with this genetic blood disorder.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia.

Transfusion medicine (Oxford, England)·2019
Same author

Hot photocarrier dynamics in organic solar cells.

Nature communications·2015
Same author

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

The Journal of pediatrics·2001
Same author

Does information collected during the residency match process predict clinical performance?

Archives of pediatrics & adolescent medicine·2001
Same author

US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN).

The Journal of pediatrics·2000
Same author

Successful cord blood transplantation for sickle cell anemia from a sibling who is human leukocyte antigen-identical: implications for comprehensive care.

Journal of pediatric hematology/oncology·2000
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Sickle cell disease (SCD) stems from a genetic mutation affecting hemoglobin, identified 35 years ago.
  • A specific curative therapy for the underlying hemoglobin abnormality remains elusive.
  • Despite this, significant progress in understanding SCD pathophysiology and natural history has been achieved.

Observation:

  • Recent progress has enhanced the understanding of SCD pathophysiology and natural history.
  • This improved understanding has directly led to significant advancements in prophylactic and supportive care strategies.

Findings:

  • Prophylactic and supportive therapies have markedly reduced morbidity and prolonged life expectancy in patients with SCD.
  • These advancements are particularly impactful for SCD manifestations affecting the spleen, lungs, and brain.

Related Experiment Videos

Implications:

  • New therapeutic strategies, including chronic transfusions, bone marrow transplantation, and hydroxyurea, offer hope for preventing hemolytic and vaso-occlusive events.
  • These evolving treatments represent a significant step forward in managing the complexities of sickle cell disease.